id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-324553-qd8249w3	Cadegiani, F. A.	An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial.	2020-10-06		.txt	text/plain	6393	402	51	The present study aimed to evaluate the effects of any early pharmacological approach to females diagnosed with COVID-19 before seven days of symptoms, as well as investigate whether HA is an additional risk factor in this population. Materials and methods: Females with symptoms for less than seven days confirmed for COVID-19 through positive real-time polymerase chain reaction (rtPCR-SARS-CoV-2) were classified and divided as non-HA, HA, and HA using spironolactone (HA-spiro) groups. Conclusions: A sensitive, early detection of COVID-19 followed by a pharmaceutical approach with different drug combinations yielded irrefutable differences compared to sex-, age-, body mass index (BMI)-, and disease-matched non-treated controls in terms of clinical outcomes, ethically disallowing placebo-control randomized clinical trials in the early stage of COVID-19 due to the marked improvements. Several different molecules demonstrated in vitro antiviral activity against SARS-CoV-2 and have been proposed as promising therapies for COVID-19 (13) , among which the most attempted drug combinations included azithromycin in the majority of the cases, in association with hydroxychloroquine, ivermectin or nitazoxanide (13, 14) .	./cache/cord-324553-qd8249w3.txt	./txt/cord-324553-qd8249w3.txt